[Antiamnesic effects divaza and its component model β-amyloid amnesia].

Area of Science:

• Neuroscience
• Pharmacology

Background:

• Alzheimer's disease models often involve beta-amyloid peptide injections to induce memory deficits.
• Investigating therapeutic interventions for amnesia and cognitive impairment is crucial for neurodegenerative disorders.

Purpose of the Study:

• To evaluate the antiamnesic activity of active antibody preparations (RA AT) against S100 (tenoten) and eNOS (impaza), and their combination (divaza).
• To assess the efficacy of these preparations in a beta-amyloid induced amnesia model in rats.

Main Methods:

• Amnesia was induced via intracerebroventricular (icv) injection of beta-amyloid fragment 25-35 peptide.
• Antiamnesic activity was assessed using behavioral tests: novel object recognition, conditioned response, and passive avoidance.
• Active antibody preparations (RA AT) to S100 (tenoten), eNOS (impaza), and their combination (divaza) were administered.

Main Results:

• RA AT S100 (tenoten) improved short-term memory (1-hour recall) in beta-amyloid treated rats.
• RA AT eNOS (impaza) was more effective for memory recall tested 24 hours later.
• The combined preparation (divaza) completely compensated for behavioral deficits, with tenoten impacting cognitive impairment and impaza addressing surgery-related symptoms.

Conclusions:

• The combined preparation divaza showed superior efficacy in ameliorating amnesia and neophobia.
• These findings support further research and development of active drugs for neurodegenerative disorder models.
• Targeting both cognitive and emotional components may be key for effective amnesia treatment.